{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hepatitis+A+%28HAV%29+vaccines&page=2", "query": { "intervention": "hepatitis A (HAV) vaccines", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 137, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hepatitis+A+%28HAV%29+vaccines&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hepatitis+A+%28HAV%29+vaccines&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T00:39:16.237Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02772003", "title": "DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis", "Hepatitis C Infection", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Electroporation-Mediated Plasmid DNA Vaccine Therapy", "type": "BIOLOGICAL" }, { "name": "HCV DNA Vaccine INO-8000", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rocakinogene Sifuplasmid", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2016-06-06", "completion_date": "2027-03-09", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Cleveland, Ohio + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02772003" }, { "nct_id": "NCT01702428", "title": "Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rubella", "Measles", "Mumps" ], "interventions": [ { "name": "Priorix", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" }, { "name": "Havrix", "type": "BIOLOGICAL" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 5016, "start_date": "2012-11-09", "completion_date": "2015-04-16", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 62, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Daly City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01702428" }, { "nct_id": "NCT00958763", "title": "Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Motivational Interviewing, Single - MIS", "type": "BEHAVIORAL" }, { "name": "Motivational Interviewing Group", "type": "BEHAVIORAL" }, { "name": "Usual Care Group - UCG", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 219, "start_date": "2006-03", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2009-08-13", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 3, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00958763" }, { "nct_id": "NCT01000974", "title": "Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilus Influenzae Type b" ], "interventions": [ { "name": "GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)", "type": "BIOLOGICAL" }, { "name": "ActHIB™", "type": "BIOLOGICAL" }, { "name": "Pentacel™", "type": "BIOLOGICAL" }, { "name": "Pediarix™", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "Rotarix™", "type": "BIOLOGICAL" }, { "name": "Engerix™-B", "type": "BIOLOGICAL" }, { "name": "Infanrix™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 4003, "start_date": "2010-06-18", "completion_date": "2013-07-17", "has_results": true, "last_update_posted_date": "2018-07-12", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 63, "location_summary": "Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Benton", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01000974" }, { "nct_id": "NCT02590068", "title": "Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Zoster vaccine live", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "50 Years to 60 Years" }, "enrollment_count": 14, "start_date": "2015-12", "completion_date": "2017-09-08", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02590068" }, { "nct_id": "NCT02057263", "title": "The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "Alendronate", "type": "DRUG" }, { "name": "Hepatitis B Vaccine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 28, "start_date": "2014-04", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057263" }, { "nct_id": "NCT05095844", "title": "National Vaccine Adverse Event Reporting Survey and Etiology", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19", "Vaccine Adverse Reaction", "Vaccine Reaction", "Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use", "Corona Virus Infection", "Blood Clot", "Thrombocytopenia", "Neuritis", "Vasculitis", "Influenza", "Guillain-Barré", "GWAS", "Genetic Sequencing" ], "interventions": [ { "name": "vaccinated", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Neuroganics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "5 Years to 99 Years" }, "enrollment_count": 100000, "start_date": "2022-03-15", "completion_date": "2024-04-01", "has_results": false, "last_update_posted_date": "2022-03-18", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 1, "location_summary": "Northglenn, Colorado", "locations": [ { "city": "Northglenn", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05095844" }, { "nct_id": "NCT01339000", "title": "Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Colon Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Glycosylated Recombinant Human Interleukin-7", "type": "DRUG" }, { "name": "Diphtheria/Tetanus Vaccine", "type": "BIOLOGICAL" }, { "name": "Polio Vaccine", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis A Vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis B Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "60 Years to 100 Years" }, "enrollment_count": 1, "start_date": "2011-04", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2016-06-22", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 2, "location_summary": "Bethesda, Maryland • New York, New York", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01339000" }, { "nct_id": "NCT01311674", "title": "Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "hepatitis B vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Emergent BioSolutions", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "20 Years to 55 Years" }, "enrollment_count": 141, "start_date": "2009-09", "completion_date": "2011-03-11", "has_results": true, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 2, "location_summary": "Altamonte Springs, Florida • Frederick, Maryland", "locations": [ { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Frederick", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01311674" }, { "nct_id": "NCT03039790", "title": "Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy Volunteers", "Norovirus" ], "interventions": [ { "name": "NoV Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 528, "start_date": "2017-02-21", "completion_date": "2021-07-22", "has_results": true, "last_update_posted_date": "2022-11-09", "last_synced_at": "2026-10-10T00:39:16.237Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03039790" } ] }